Health

High relapse rate of schizophrenia has become the focus of World Health. Due to the characteristics of the disease, schizophrenia is a chronic recurrent persistent disease, the disease easily repeated. Each may lead to relapse in patients with permanent brain damage, impaired cognitive function, a further decline in social function; for the families of patients, relapse of the disease means that the deterioration of their loved ones and a series of mandatory in-patient treatment, must assume a greater the financial burden and emotional pressure; for medical workers, the treatment of recurrence will increase the difficulty and, ultimately, the prognosis is not ideal. Therefore effective in preventing relapse of schizophrenia has become an urgent need to solve.
June 17 in organizing the "ADHES China found that" the whole country to start the meeting, the Chinese Medical Association chairman of psychiatry credits will be announced the launch of Professor Zhou Dongfeng schizophrenic patients for risk factors for relapse and hospitalization investigation. Professor Zhou also introduced: "the treatment of patients with schizophrenia or in part from the non-compliance leading to relapse and re-hospitalization in patients with the most important factor. Today is the attempt to start the investigation of multiple factors of non-compliance found in the importance of different factors the extent of the effect of better treatment for active exploration. "
Lead to frequent recurrence of mental illness is one of the root causes of medication in patients with poor compliance. The so-called compliance refers to the degree of patient compliance with doctor's advice. Professor He Yanling today, so read at the first national survey of schizophrenia outpatients compliance results: "At present, the treatment of patients with schizophrenia is still far from satisfactory compliance, at least about 3 in patients with schizophrenia into compliance issue. patients, family groups, 30% of the respondents admitted that the course of treatment has its own drug, by drug or refuse medication; investigation group from the number of doctors is even more pessimistic, doctors believe that patients themselves are the drug , by drugs or refuse medication, and a quarter of the patients had forgotten medication.
The findings of the outpatients also confirmed that there are still 38% of patients worried about side effects of drug withdrawal, 20% of patients with physical handicaps as a result of drug treatment.
Schizophrenia treatment to improve compliance and help patients return to society a long-term drug therapy in patients with schizophrenia may make the treatment of loss of confidence. Frequent leakage of drugs will inevitably lead to disease recurrence, and even had deteriorated once again hospitalized. When patients relapse after several times, each cycle of the disease will be needed to restore a longer period of time, the effect of antipsychotics will also be reduced, over time, gradually increase the difficulty of treatment.
Compliance with drug treatment of schizophrenia is the key to the success of one of the factors, so through various efforts to improve patient compliance is very important for the treatment of schizophrenia.
The experts agreed that: "The development and application of new drugs is to improve the treatment compliance of the most effective way." With the new type of atypical neuroleptic drugs have come out better in terms of curative effects, but also to improve the traditional drug prone to the stiffness, slow movement, trembling, drooling, such as adverse reactions, but the patient's compliance has not been clear improvement. Research has demonstrated that oral administration of atypical antipsychotics in the treatment of 18-month interruption of 75%.
Means in the treatment of atypical neuroleptic drugs has been a long-acting injection for doctors, patients with new solutions. The new long-acting injection "Hengde" adopted "Medisorb microspheres technology" to make active pharmaceutical ingredients break down in the body, stable and sustainable, continuing to play a pharmacodynamics two weeks, and completely decomposed into water and carbon dioxide metabolism in vitro sent, relatively safe. As a new generation of long-acting antipsychotics, "EVER" to ensure stable and sustainable delivery of drugs that can effectively improve the patient's medication compliance, protection of vulnerable patients with recurrence of the impact from the effect of interruption; "Hengde" so that doctors can more easy to monitor the progress of the disease, and patients and medical team to promote regular contacts. A new generation of long-acting injection injection "Ever", for example, and application is an important milestone in the treatment of schizophrenia.
On the other hand, new treatment modalities to help patients and their families are also in the course of treatment to be more support and encouragement of community mental illness treatment modalities for patients with schizophrenia to provide a comprehensive and thoughtful services, referral of patients with periodic reminders to help patients have a more independent and free life, enhance self-confidence and self-esteem, and eventually return to society, in order to create the value of the family and society.
"We have no reason to because they feel does not match the real world and blame them, because they feel is very real to them, we have no reason not to help them, because they can not distinguish between the self." To help patients through the treatment, restore social functions return to the spirit of community has become a new therapeutic target specialists.